The early-phase drug trials in pancreatic cancer have therefore largely focused on the indirect inhibition of RAS, in particular, targeting downstream signaling such as the RAF-MEK-ERK pathway [13]. This evidence concerns the gene RAF1 and familial pancreatic carcinoma.